Eli Lilly & Co. (LLY) & Incyte (INCY) Report Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib

Incyte (INCY) Tops Q4 EPS by 8c, Revenues Beat

February 13, 2020 7:07 AM EST

Incyte (NASDAQ: INCY) reported Q4 EPS of $0.65, $0.08 better than the analyst estimate of $0.57. Revenue for the quarter came in at $579.39 million versus the consensus estimate of $575.6 million.

Total product and royalty revenues of $579 million (+24%) in 4Q 2019 and $2.1 billion (+22%) for the full year 2019; Jakafi® (ruxolitinib) revenues of $466 million (+23%) in 4Q... More

Mizuho Securities Reiterates Neutral Rating on Eli Lilly (LLY)

February 11, 2020 7:19 AM EST

Mizuho Securities analyst Vamil Divan reiterated a Neutral rating and $148.00 price target on Eli Lilly (NYSE: LLY) following the company's announcement that the DIAN-TU study did not meet the primary endpoint of showing an improvement for the drug over placebo. Divan believes some... More

Eli Lilly Canada (LLY) Announces Health Canada has approved TALTZ for Treatment of Active Ankylosing Spondylitis

February 11, 2020 6:52 AM EST

Eli Lilly Canada (NYSE: LLY) announced today that Health Canada approved TALTZ® (ixekizumab) on February 4, 2020, for the treatment of adult patients with active ankylosing spondylitis (AS), which is also known as radiographic axial spondyloarthritis (r-axSpA), who have responded inadequately to, or are intolerant to, conventional therapy. This is the third indication for TALTZ, which was first approved by Health Canada for moderate- to severe plaque psoriasis and psoriatic arthritis in 2016 and 2018, respectively.

People living with ankylosing spondylitis deal with a considerable amount of pain and anxiety. If left... More

Eagle Pharmaceuticals (EGRX) Receives Final FDA Approval for PEMFEXY

February 10, 2020 9:54 AM EST

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its novel product, PEMFEXY (pemetrexed for injection), a branded alternative to ALIMTA®.

We are pleased to receive final... More

Pre-Open Stock Movers 2/10: (VTVT) (EPC) (TSLA) Higher (ABUS) (BHVN) (LLY) Lower (more...)

February 10, 2020 9:21 AM EST

Today's Pre-Open Stock Movers

vTv Therapeutics Inc. (Nasdaq: VTVT) 79.5% HIGHER; announced positive results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes (T1D). TTP399 is a novel, liver-selective glucokinase activator taken once a day. The 12-week trial investigated the efficacy and safety of 800 mg of TTP399 compared with placebo in 85 people with type 1 diabetes on optimized insulin therapy. The study was conducted with support from JDRF International (JDRF), the leading provider of T1D research funding... More

Lilly (LLY) announces analysis performed by Washington University School of Medicine in DIAN-TU Study showed solanezumab did not meet primary endpoint

February 10, 2020 6:29 AM EST

Eli Lilly and Company (NYSE: LLY) today announced that the analysis performed by Washington University School of Medicine in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study showed that solanezumab did not meet the primary endpoint. Additional analyses of secondary endpoints and biomarkers are ongoing by Washington University and Lilly. Results will be presented at the Advances in Alzheimer's and Parkinson's Therapies (AAT-AD/PD) Focus Meeting in April of 2020. At this time, Lilly does not plan to pursue a submission for solanezumab in people with dominantly inherited Alzheimer's disease (DIAD), also known... More